The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 2020

[F1Requirements on person notified as a close contact of a person who has tested positive for coronavirusE+W

This adran has no associated Memorandwm Esboniadol

2B.—(1) This regulation applies where an adult is notified by a relevant person, other than by means of the NHS Covid 19 smartphone app developed and operated by the Secretary of State, that—

(a)they have had close contact with someone who has tested positive for coronavirus, F2...

F3(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(2) Where paragraph (1)(a) applies, the person notified must self-isolate for the period of self-isolation unless [F4paragraph (6) applies or]—

(a)they are taking part in coronavirus related research, and

(b)that research cannot be completed if they self-isolate.

F5(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(4) In addition, P F6... must if, requested by a relevant person, notify that person of the address at which P will remain pursuant to the requirement in regulation 2(1)(a).

(5) If a relevant person notifies P F7... that a notification referred to in paragraph (1) in respect of P is withdrawn, such notification is deemed never to have been given for the purposes of these Regulations.

[F8(6) This paragraph applies if—

(a)the person (“NP”) has completed a course of doses of an authorised vaccine, and

(i)that course of doses was administered to NP in the United Kingdom, and

(ii)the day on which NP had the close contact which resulted in the notification described in paragraph (1) is more than 14 days after the day on which NP completed that course of doses,

(b)NP has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in the United Kingdom in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004, or

(c)NP is able to provide evidence that, for clinical reasons, NP should not be vaccinated with any authorised vaccine.

(7) For the purposes of paragraph (6), a person has completed a course of doses if that person has received the complete course of doses specified—

(a)in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or

(b)in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc) of the Human Medicines Regulations 2012 for the authorised vaccine.

(8) In this regulation—

“authorised vaccine” means a medicinal product—

(a)

authorised for supply in the United Kingdom in accordance with a marketing authorisation, or

(b)

authorised by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012,

for vaccination against coronavirus;

“clinical trial” has the meaning given in regulation 2(1) (interpretation) of the Medicines for Human Use (Clinical Trials) Regulations 2004;

“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012;

“marketing authorisation” has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012;

“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012.]]

Textual Amendments